Vas Narasimhan, Novartis CEO (Jason Alden/Bloomberg via Getty Images)
Novartis gets the green light to start marketing its next prospective blockbuster. And they're charging a premium for convenience
A last-minute holdup at the FDA has been cleared up as regulators stamped their approval on Novartis’ new multiple sclerosis drug ofatumumab.
The FDA had …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
